The U.S. Food and Drug Administration has approved UCB's Bimzelx (bimekizumab-bkzx) for the treatment of adults with moderate ...

The mechanisms underlying skin renewal are still poorly understood. Interleukin-38 (IL-38), a protein involved in regulating inflammatory responses, could be a game changer. A team has observed it for ...

FDA Project Team supports the company’s proposed Phase 3 trial strategy, including overall trial design, target patient population, treatment ...

The mechanisms underlying skin renewal are still poorly understood. Interleukin-38 (IL-38), a protein involved in regulating ...

Researchers discover that capillary obstruction in diabetes, triggered by elevated interleukin-10 signaling, may contribute to cognitive deficits independent of blood sugar levels. In a recent study ...

FDA approves UCB's Bimzelx for adults with moderate to severe hidradenitis suppurativa, supported by Phase 3 trials showing significant symptom improvement.

Autoimmunity Biosolutions has closed a seed financing to support its work advancing a next-generation, immuno-corrective therapy for autoimmune diseases. The company’s approach targets a branch of the ...

Researchers discovered an unexpected link between zinc deficiency, the pro-inflammatory cytokine interleukin-13 (IL-13), and Acinetobacter baumannii lung infection and demonstrated that blocking IL-13 ...

An expert explained how a patient’s own T cells can be extracted, manufactured and infused back into the body as a treatment ...

The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...

Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical stage biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with cancer and inflammatory diseases, today ...

The Food and Drug Administration has granted Fast Track designation to GNSC-001 for the treatment of osteoarthritis of the knee.